A case report published in Cureus on August 26, 2026 describes the emergency-care challenges that followed use of an online-sourced product marketed as retatrutide by a man with longstanding type 1 diabetes. The report is a warning about unregulated research peptides and a medically vulnerable situation—not evidence that pharmaceutical-grade retatrutide caused diabetic ketoacidosis or liver injury.
What happened in the case
The patient, a man in his mid-30s with a 17-year history of type 1 diabetes, self-administered a powder labelled as retatrutide after buying it online. He reconstituted the product himself and intended to inject 0.5 mg. Within hours he developed nausea, persistent vomiting, and diarrhoea. His partner had used the same preparation and also developed gastrointestinal symptoms. Both had also eaten potentially contaminated chicken soup.
When the patient reached hospital, he had hyperglycaemia, ketonaemia, dehydration, acute kidney injury, and coffee-ground vomit. His peak blood ketone level was 4.3 mmol/L. He had omitted insulin while unable to eat and because he feared hypoglycaemia. Although he did not develop diabetic ketoacidosis, he required intravenous fluids and insulin. During recovery, recurrent hypoglycaemia required intravenous dextrose and adjustment of insulin treatment. Stool testing later identified Shigella flexneri, providing a confirmed infectious explanation for at least part of the illness.
The product was not independently analysed or verified to contain retatrutide. The authors therefore cannot determine how much the marketed product contributed to the gastrointestinal symptoms or metabolic deterioration. They point to the timing of exposure, similar symptoms in another exposed person, and the known gastrointestinal effects reported with incretin therapies as reasons the exposure may have worsened the consequences of infection and reduced food and fluid intake.
Why type 1 diabetes changes the risk
People with type 1 diabetes depend on exogenous insulin to suppress ketone production. Vomiting, diarrhoea, dehydration, infection, reduced carbohydrate intake, and omitted insulin can combine rapidly to produce dangerous ketonaemia. The report also illustrates why clinicians need to ask directly about prescribed medicines, supplements, and non-prescribed or online products when assessing unexplained gastrointestinal illness or metabolic decompensation.
Retatrutide remains investigational. It has no established role in type 1 diabetes, and the online product in this report was not the controlled pharmaceutical material used in Eli Lilly clinical trials.
Canadian context
For Canadians, the case reinforces that a website label or “research use only” disclaimer does not establish a product’s identity, concentration, sterility, or safety. Retatrutide is not approved by Health Canada and cannot be lawfully purchased as a routine weight-loss medicine. Regulated access is limited to an authorized clinical trial or, in appropriate circumstances, a physician-led request through Health Canada’s Special Access Programme. Neither pathway involves self-reconstituting a powder bought from an online vendor.
Anyone who becomes acutely ill after using an unregulated injectable should seek urgent medical care and tell clinicians exactly what was taken. People with diabetes should follow their healthcare team’s sick-day instructions rather than stopping insulin without advice.